A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

NCT ID: NCT05312411

Last Updated: 2025-11-20

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-20
• Study Completion Date: 2040-05-31

Brief Summary

The purpose of this study is to see if a new treatment could help patients who have osteosarcoma that does not go away with treatment (is refractory) or comes back after treatment (is recurrent).This study is testing a combination of study therapies, UB-TT170 and genetically modified chimeric antigen receptor T lymphocyte (CAR T) cells, which work together in a way that is different from chemotherapy.

In this study, researchers will take some of your blood and remove the T cells in a process called "apheresis". Then the T cells are taken to a lab and changed to CAR T cells that recognize the flags from UB-TT170. Once researchers think they have grown enough CAR T cells, called antiFL(FITC-E2) CAR T cells, to fight your cancer, you may get some chemotherapy to make room in your body for the new cells and then have those cells put back in your body.

A few days after the you get your CAR T cell infusion you will start to get infusions of UB-TT170, with the dose slowly increasing for the first few infusions until you have reached a maximum dose that you will get on a regular schedule. The UB-TT170 will attach to your tumor cells and flag them so that they attract the CAR T cells. When the CAR T cells see the labeled tumor cells they can kill the tumor cells.

The active part of the study lasts about 8 months, and if you get the CAR T cell infusion you will be in long-term follow-up for 15 years.

Conditions

Osteosarcoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

UB-TT170 following SCRI-E2CAR_EGFrtv1

Following CAR T cell administration, subjects will receive a first Course of 3 escalating doses of UB-TT170 over 2 weeks followed by fixed weekly dosing for 2 weeks. If eligible, subjects may proceed to Courses 2 - 4 consisting of 7 weekly doses of UB-TT170.

Group Type: EXPERIMENTAL

SCRI-E2CAR_EGFRtv1

Intervention Type: BIOLOGICAL

Autologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)

UB_TT170

Intervention Type: DRUG

Bispecific small molecule adapter formulated with phosphate buffered saline

Interventions

SCRI-E2CAR_EGFRtv1

Autologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)

Intervention Type: BIOLOGICAL

UB_TT170

Bispecific small molecule adapter formulated with phosphate buffered saline

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Refractory or recurrent/progressive osteosarcoma that has failed first line therapy for Osteosarcoma per NCCN or upfront Children's Oncology Group clinical trial and is not amenable to surgical resection (must meet one of the following):

1. New site of measurable disease by radiographic imaging or histologic confirmation

2. New site of evaluable disease by radiographic imaging (including FDG-PET) or histologic confirmation

3. Greater than 20% increase in at least one tumor dimension documented by CT/MRI, AND a maximum absolute increase of 5 mm in longest dimension of existing lesion(s) (previously irradiated lesions may be included)

4. Persistent measurable disease or FDG-PET avid bone metastasis that has failed to achieve complete remission to upfront conventional therapy (surgery, radiotherapy and/or chemotherapy)

• Able to tolerate apheresis, including placement of temporary apheresis catheter, if necessary, or already has an apheresis product available for use in manufacturing
• Life expectancy ≥ 8 weeks
• Lansky or Karnofsky score ≥ 50
• Anti-cancer agents, radiotherapy, cytoxic chemotherapy, biologic therapy, anti-tumor antibody therapy, genetically modified cell therapy, and, if no apheresis product available, corticosteroid therapy (excluding physiologic replacement), discontinued within protocol specified wash-out period
• Adequate hematologic, renal, hepatic, cardiac, and respiratory function.
• Negative HIV, hepatitis B and C test within 3 months
• If of child-bearing or fathering potential, willing to use highly effective contraception through 12 months following final stud drug infusion

Exclusion Criteria

• Active malignancy other than primary malignant solid tumor diagnosis (CNS intracranial metastases are allowed)
• Ongoing, symptomatic CNS pathology requiring medical intervention
• Receiving external beam radiotherapy
• Presence of active, severe infection
• Primary immunodeficiency syndrome
• Pregnant or breast feeding
• Unwilling to provide consent/assent for study participation, including 15 year follow up
• Presence of any condition that, in the opinion of the investigator, would prohibit the subject from undergoing treatment under this protocol.

• Minimum Eligible Age: 15 Years
• Maximum Eligible Age: 30 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Umoja Biopharma

INDUSTRY

Sponsor Role: collaborator

Seattle Children's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Colleen Annesley

Medical Director, Seattle Children's Therapeutics

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Catherine Albert, MD

Role: PRINCIPAL_INVESTIGATOR

Seattle Children's Hospital

Locations

Seattle Children's Hospital

Seattle, Washington, United States

Countries

United States

Other Identifiers

ENLIGHTen-01

Identifier Type: -

Identifier Source: org_study_id